Last reviewed · How we verify

NCT04621526

Monitored Anesthesia Care: Dexmedetomidine-Ketamine Versus Dexmedetomidine- Propofol For Chronic Subdural Hematoma

Completed Phase 1, PHASE2 Last updated 17 October 2023
What this trial tests

Phase 1, PHASE2 trial testing dexmedetomidine- ketamine in Conscious Sedation in 56 participants. Completed in 30 August 2023.

Timeline
10 November 2020
Primary endpoint
30 August 2023
30 August 2023

Quick facts

Lead sponsorZagazig University
PhasePhase 1, PHASE2
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment56
Start date10 November 2020
Primary completion30 August 2023
Estimated completion30 August 2023
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Zagazig University

Who can join

Adults 50 to 80, any sex, with Conscious Sedation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Inadequate sedation and analgesia indicated by intraoperative movements are markers of inadequate MAC during burr-hole surgery for chronic subdural hematoma evacuation especially when general anesthesia poses high risk for the patients. Dexmedetomidine, ketamine, propofol intravenous infusion and other agents was used to provide monitored anesthesia care with variable success if used as solitary agents as each drug has its limited use.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Conscious Sedation

Currently open trials in the same condition.

Other Zagazig University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04621526.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing